ECSP099398A - Compuestos y métodos para inhibir la interacción de las proteínas bcl con agentes aglutinantes - Google Patents

Compuestos y métodos para inhibir la interacción de las proteínas bcl con agentes aglutinantes

Info

Publication number
ECSP099398A
ECSP099398A EC2009009398A ECSP099398A ECSP099398A EC SP099398 A ECSP099398 A EC SP099398A EC 2009009398 A EC2009009398 A EC 2009009398A EC SP099398 A ECSP099398 A EC SP099398A EC SP099398 A ECSP099398 A EC SP099398A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
inhibit
interaction
binding agents
Prior art date
Application number
EC2009009398A
Other languages
English (en)
Inventor
Edward B Holson
Brian T Hopkins
Nii O Koney
Daniel A Snyder
Alfredo C Castro
Thomas T Tibbitts
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of ECSP099398A publication Critical patent/ECSP099398A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un aspecto del presente invento se relaciona con los compuestos heterocíclicos que enlazan las proteínas bcl y bloquean la función Bcl. Otro de los aspectos del presente invento se relaciona con las composiciones que comprenden un compuesto heterocíclico del invento. El presente invento presenta métodos para tratar y modular los desórdenes relacionados con la hiperproliferación, tal como el cáncer.
EC2009009398A 2006-11-15 2009-06-09 Compuestos y métodos para inhibir la interacción de las proteínas bcl con agentes aglutinantes ECSP099398A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/600,332 US7842815B2 (en) 2004-06-17 2006-11-15 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

Publications (1)

Publication Number Publication Date
ECSP099398A true ECSP099398A (es) 2009-07-31

Family

ID=39064388

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009398A ECSP099398A (es) 2006-11-15 2009-06-09 Compuestos y métodos para inhibir la interacción de las proteínas bcl con agentes aglutinantes

Country Status (20)

Country Link
US (2) US7842815B2 (es)
EP (1) EP2094673B1 (es)
JP (2) JP2010510214A (es)
KR (1) KR101530721B1 (es)
CN (1) CN101583606B (es)
AU (1) AU2007319848B2 (es)
BR (1) BRPI0718606A2 (es)
CA (1) CA2669596C (es)
EC (1) ECSP099398A (es)
ES (1) ES2537762T3 (es)
GT (1) GT200900123A (es)
IL (1) IL198597A (es)
MA (1) MA31067B1 (es)
MX (1) MX2009005184A (es)
MY (1) MY156754A (es)
NO (1) NO20092306L (es)
NZ (1) NZ577243A (es)
RU (1) RU2449996C2 (es)
TN (1) TN2009000182A1 (es)
WO (1) WO2008060569A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
EP2242503A4 (en) * 2008-02-08 2012-04-25 Aileron Therapeutics Inc THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
EP2812695A4 (en) 2012-02-06 2015-12-02 Discoverx Corp DETECTION OF INTRA-CELLULAR BINDING EVENTS BY MEASUREMENT OF THE PROTEIN FILL
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN103656642A (zh) * 2012-08-31 2014-03-26 中国科学院上海生命科学研究院 预防和治疗结直肠癌的方法和试剂
ES2774932T3 (es) 2012-11-14 2020-07-23 Cj Cheiljedang Corp Producción de sales de 4-hidroxibutirato utilizando materias primas de base biológica
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
WO2017172826A1 (en) 2016-03-28 2017-10-05 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
JP7168580B2 (ja) * 2017-04-05 2022-11-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状化合物およびその使用
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
EP4175644A1 (en) 2020-07-06 2023-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
WO1991017748A1 (de) 1990-05-18 1991-11-28 Hoechst Aktiengesellschaft Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
ES2134870T3 (es) * 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
ES2154326T3 (es) 1993-11-24 2001-04-01 Du Pont Pharm Co Antagonistas de receptor de fibrinogeno de isoxazolina e isoxazol.
CA2185019C (en) 1994-03-09 2000-08-08 Pfizer Limited Isoxazoline compounds as inhibitors of tnf release
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
JP2000516234A (ja) 1996-08-16 2000-12-05 デュポン ファーマシューティカルズ カンパニー アミジノフェニル―ピロリジン類、アミジノフェニル―ピロリン類、およびアミジノフェニル―イソオキサゾリジン類およびそれらの誘導体
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
WO1998050030A1 (en) 1997-05-07 1998-11-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
WO2001016115A1 (en) 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
AU2002305769B2 (en) 2001-05-30 2007-07-19 Georgetown University Small molecule antagonists of Bcl2 family proteins
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
EP1768966B1 (en) 2004-06-17 2012-03-07 Infinity Discovery, Inc. Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners
US20060020004A1 (en) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Isoxazolidine compounds for treatment of bacterial infections
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法

Also Published As

Publication number Publication date
CN101583606B (zh) 2015-04-08
US7842815B2 (en) 2010-11-30
JP2010510214A (ja) 2010-04-02
EP2094673B1 (en) 2015-04-08
IL198597A (en) 2014-03-31
KR20090082284A (ko) 2009-07-29
RU2449996C2 (ru) 2012-05-10
MX2009005184A (es) 2009-10-12
US20080306127A9 (en) 2008-12-11
CN101583606A (zh) 2009-11-18
NO20092306L (no) 2009-08-17
US20110160259A1 (en) 2011-06-30
AU2007319848B2 (en) 2012-05-03
TN2009000182A1 (en) 2010-10-18
US8461191B2 (en) 2013-06-11
MA31067B1 (fr) 2010-01-04
ES2537762T3 (es) 2015-06-11
IL198597A0 (en) 2010-02-17
BRPI0718606A2 (pt) 2013-12-17
HK1130057A1 (en) 2009-12-18
RU2009121808A (ru) 2010-12-20
CA2669596C (en) 2014-09-30
GT200900123A (es) 2011-09-02
WO2008060569A1 (en) 2008-05-22
CA2669596A1 (en) 2008-05-22
NZ577243A (en) 2011-12-22
JP2014055156A (ja) 2014-03-27
US20070161690A1 (en) 2007-07-12
AU2007319848A1 (en) 2008-05-22
EP2094673A1 (en) 2009-09-02
MY156754A (en) 2016-03-31
KR101530721B1 (ko) 2015-06-22

Similar Documents

Publication Publication Date Title
ECSP099398A (es) Compuestos y métodos para inhibir la interacción de las proteínas bcl con agentes aglutinantes
ECSP088607A (es) Compuestos y métodos para inhibir la interacción de las proteínas bcl con las parejas de unión
ECSP067099A (es) Compuestos y métodos para inhibir la interacción de las proteínas bcl con los componentes de enlace
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CR11361A (es) Moleculas y metodos para modular el componente de complemento
CL2007002424A1 (es) Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer.
EA201490644A1 (ru) Терапевтические пептиды
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
GT200600328A (es) Derivados de isoquinolona sustituidos con piperidinilo
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CR9604A (es) Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
BRPI0921685A2 (pt) composição tópica compreendendo uma combinação de pelo menos dois agentes que melhoram a penetração.
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
ECSP10010705A (es) Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa
GT200800285A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
UY31688A1 (es) Plaguicidas
GT200800102A (es) Compuestos y metodos para inhibir la interaccion de proteinas bcl con moleculas de enlace
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
MX2019007067A (es) Inhibidores de azepano de la interacción menina-mll.